Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Ann Oncol ; 24(3): 749-55, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23131388

ABSTRACT

BACKGROUND: The metabolic syndrome (MS) might increase the risk of cardiovascular disease in testicular cancer (TC) survivors. We investigated its prevalence, development, vascular implications, and the role of gonadal function. METHODS: TC survivors treated with chemotherapy and follow-up ≥3 years (N = 370, study I) were retrospectively evaluated for the development of cardiovascular risk factors. A subgroup followed 3-20 years (N = 173, study II) was compared with controls (N = 1085) for MS prevalence and evaluated for vascular function. RESULTS: In TC survivors (study I), 24% developed overweight, 24% hypercholesterolemia, and 30% hypertension, after median follow-up of 1.7, 0.9, and 5.1 years, respectively. At the median follow-up of 5 years (study II), 25% of survivors have the MS {odds ratio (OR) 2.2, [95% confidence interval (CI) 1.5-3.3] compared with controls}. Survivors with MS have features of inflammation and prothrombotic state, increased carotid artery intima-media thickness. Survivors with testosterone levels <15 nmol/l (22%) have an increased risk of the MS (OR 4.1, 95% CI 1.8-9.3). CONCLUSIONS: The current data suggest that the MS occurs at earlier age in TC survivors treated with chemotherapy compared with controls and is accompanied by early signs of atherosclerosis. As low testosterone may have a causal role, it is a target for interventions.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cardiovascular Diseases/chemically induced , Metabolic Syndrome/chemically induced , Testicular Neoplasms/drug therapy , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cardiovascular Diseases/epidemiology , Cisplatin/administration & dosage , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Male , Metabolic Syndrome/epidemiology , Middle Aged , Overweight/chemically induced , Overweight/epidemiology , Prevalence , ROC Curve , Retrospective Studies , Risk Factors , Young Adult
2.
Ann Oncol ; 21(1): 104-8, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19605510

ABSTRACT

BACKGROUND: Patients with elevated human chorionic gonadotrophin (HCG) can have hyperthyroidism. We assessed the prevalence of hyperthyroidism in patients presenting with disseminated non-seminomatous germ-cell tumors (NSGCT). PATIENTS AND METHODS: In all patients with metastatic NSGCT who started chemotherapy at our center from April 2001 to April 2007, thyroid function was analyzed. The association between thyroid function and HCG level was examined and the frequency of hyperthyroidism in patients with low (<5000 IU/l), intermediate (> or = 5000 but <50 000 IU/l) and high (> or = 50 000 IU/l) serum HCG was assessed. RESULTS: For 144 of 148 eligible patients, thyroid function tests were available. Five patients with hyperthyroidism (3.5%) were identified, who all had high-serum HCG (mean 1 325 147 IU/l). Fifty percent of the patients with high HCG levels had hyperthyroidism versus 0% of the patients with HCG <50 000 IU/l (P < 0.001). Free thyroxin levels normalized within 26 days after starting chemotherapy in all patients. CONCLUSIONS: Hyperthyroidism frequently accompanies NSGCT with highly elevated HCG. Since its symptoms overlap with those of extensive metastatic disease, it may not be recognized. Thyroid function should be assessed in patients with high HCG levels and symptomatic hyperthyroidism should be treated temporarily with beta-blockade or antithyroidal medication.


Subject(s)
Hyperthyroidism/epidemiology , Neoplasms, Germ Cell and Embryonal/complications , Paraneoplastic Endocrine Syndromes/epidemiology , Testicular Neoplasms/complications , Adolescent , Adult , Chorionic Gonadotropin/blood , Humans , Hyperthyroidism/etiology , Male , Middle Aged , Neoplasms, Germ Cell and Embryonal/blood , Paraneoplastic Endocrine Syndromes/etiology , Prevalence , Testicular Neoplasms/blood , Young Adult
3.
Br J Cancer ; 100(12): 1861-6, 2009 Jun 16.
Article in English | MEDLINE | ID: mdl-19455138

ABSTRACT

Long-term cardiovascular morbidity is increasingly observed in chemotherapy-treated testicular cancer survivors, but little is known of early sub-clinical changes in cardiac function. We prospectively evaluated cardiac function in testicular cancer patients by echocardiography. Systolic (Wall Motion Score Index) and diastolic (E/A-ratio and Tissue Velocity Imaging (TVI)) parameters, and serum levels of N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) were assessed before the start of chemotherapy and 1 year later. Echocardiography data were compared with an age-matched group of healthy controls. Forty-two patients treated with bleomycin, etoposide and cisplatin were evaluated (median age 27 years, range 18-50). Systolic function and E/A-ratio did not change, whereas the median TVI decreased (12.0 vs 10.0 cms(-1); P=0.002). Median levels of NT-proBNP increased (5 vs 18 pmoll(-1), P=0.034). Compared with controls, TVI before the start of chemotherapy was not significantly different. In conclusion, we found that at a median of 10 months after cisplatin-based treatment for testicular cancer, TVI decreased significantly, indicating a deterioration of diastolic cardiac function. Serum levels of NT-proBNP increased. The prognostic significance of these changes for future cardiovascular morbidity is not clear.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Testicular Neoplasms/drug therapy , Ventricular Dysfunction, Left/chemically induced , Adolescent , Adult , Bleomycin/administration & dosage , Cisplatin/administration & dosage , Cohort Studies , Echocardiography , Etoposide/administration & dosage , Heart/physiopathology , Humans , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Orchiectomy , Peptide Fragments/blood , Prognosis , Prospective Studies , Risk Factors , Testicular Neoplasms/blood , Testicular Neoplasms/physiopathology , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/physiopathology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...